Araclon Biotech Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 22

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $10.9M

Araclon Biotech General Information

Description

Operator of a biotechnology company intended for the research and development of therapies and methods for the diagnosis of degenerative diseases. The company is primarily engaged in the development of tests for the analysis of β-amyloid peptides in human plasma, a precursor for diagnosing Alzheimer's disease and also developing immunotherapy vaccines for tackling those β-amyloid peptides, enabling physicians to prevent the disease or delay the onset of symptoms.

Contact Information

Website
www.araclon.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • Vía Hispanidad, 21
  • 50009 Zaragoza
  • Spain
+34 976
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Vertical(s)
Corporate Office
  • Vía Hispanidad, 21
  • 50009 Zaragoza
  • Spain
+34 976

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Araclon Biotech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 29-Feb-2012 $10.9M Completed Generating Revenue
2. IBO 15-Feb-2012 Completed Generating Revenue
1. Early Stage VC Completed Generating Revenue
To view Araclon Biotech’s complete valuation and funding history, request access »

Araclon Biotech Patents

Araclon Biotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021262526-A1 Methods for quantification of amyloid beta peptides in plasma by mass spectrometry Pending 29-Apr-2020
CA-3175681-A1 Methods for quantification of amyloid beta peptides in plasma by mass spectrometry Pending 29-Apr-2020
EP-4145134-A1 Methods for quantification of amyloid beta peptides in plasma by mass spectrometry Pending 29-Apr-2020
US-20230258651-A1 Methods for quantification of amyloid beta peptides in plasma by mass spectrometry Pending 29-Apr-2020
ES-2571055-B1 Amyloid conjugate and its uses and procedures Active 15-Feb-2016 A61K38/1767
To view Araclon Biotech’s complete patent history, request access »

Araclon Biotech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Araclon Biotech Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Going Investment PE/Buyout Minority
Mobius Venture Capital Venture Capital Minority
VIA Technologies Corporation Minority
To view Araclon Biotech’s complete investors history, request access »

Araclon Biotech FAQs

  • When was Araclon Biotech founded?

    Araclon Biotech was founded in 2004.

  • Where is Araclon Biotech headquartered?

    Araclon Biotech is headquartered in Zaragoza, Spain.

  • What is the size of Araclon Biotech?

    Araclon Biotech has 22 total employees.

  • What industry is Araclon Biotech in?

    Araclon Biotech’s primary industry is Drug Discovery.

  • Is Araclon Biotech a private or public company?

    Araclon Biotech is a Private company.

  • What is the current valuation of Araclon Biotech?

    The current valuation of Araclon Biotech is .

  • What is Araclon Biotech’s current revenue?

    The current revenue for Araclon Biotech is .

  • Who are Araclon Biotech’s investors?

    Going Investment, Mobius Venture Capital, and VIA Technologies have invested in Araclon Biotech.

  • When was Araclon Biotech acquired?

    Araclon Biotech was acquired on 29-Feb-2012.

  • Who acquired Araclon Biotech?

    Araclon Biotech was acquired by Grifols.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »